Related Experiment Videos
Arrhythmogenic right-ventricular dysplasia/cardiomyopathy.
1Division of Cardiology, Johns Hopkins University School of Medicine, Baltimore, Maryland 21287, USA. hcalkins@jhmi.edu
Current Opinion in Cardiology
|December 16, 2005
Summary
Arrhythmogenic right-ventricular dysplasia (ARVD) diagnosis is evolving with MRI, while genetic insights point to desmosomal mutations. Implantable cardioverter defibrillators are key for managing ARVD patients and preventing sudden cardiac death.
Area of Science:
- Cardiology
- Genetics
- Medical Imaging
Background:
- Arrhythmogenic right-ventricular dysplasia (ARVD) is a rare inherited condition.
- It leads to right-ventricular dysfunction and life-threatening ventricular arrhythmias.
Purpose of the Study:
- To review recent advancements in diagnosing ARVD.
- To explore the genetic underpinnings of ARVD.
- To discuss current management strategies for ARVD patients.
Main Methods:
- Review of recent literature on ARVD diagnosis, genetics, and management.
- Focus on magnetic resonance imaging (MRI) in diagnosis.
- Analysis of genetic mutations, particularly in desmosomal proteins.
- Evaluation of implantable cardioverter defibrillator (ICD) therapy outcomes.
Main Results:
- Magnetic resonance imaging (MRI) is a sensitive diagnostic tool for ARVD but can lead to overdiagnosis.
- Genetic research identifies mutations in desmosomal junction proteins as a primary cause of ARVD.
- Implantable cardioverter defibrillators (ICDs) are crucial for preventing sudden cardiac death in ARVD patients meeting specific criteria.
Conclusions:
- Recent findings significantly impact the evaluation and management of ARVD.
- Understanding the genetic basis and refining diagnostic tools like MRI are critical.
- ICD therapy remains a cornerstone in managing ARVD to mitigate risks.